Spectrum of Autoimmune Bullous Diseases in Northern Greece. A 4-year Retrospective Study and Review of the Literature.

Bullous Diseases Unit at the 2nd Department of Dermatology and Venereology, Aristotle University of Thessaloniki was founded with the aim to provide the optimal diagnostic approach and treatment of patients with autoimmune bullous diseases (AΙBD). We processed all AIBD files of patients diagnosed from 2011 to 2014 in order to record all epidemiological data and therapeutic manipulations during monitoring. 57 patients were diagnosed with intraepidermal and 62 with subepidermal bullous diseases. There were 51 cases (89%) of pemphigus vulgaris (PV) and 6 (11%) of pemphigus foliaceus (PF), whereas 45 (73%) patients were diagnosed with bullous pemphigoid (BP), 9 (14%) with mucous membrane pemphigoid (MMP), 3 (5%) with pemphigoid gestationis (PG), 3 (5%) with linear IgA dermatosis (LAD), 1 (2%) with epidermolysis bullosa aquisita (EBA), and 1 patient with an undefined subepidermal AIBD. The mean age of patients within the pemphigus spectrum was 57 years. In the pemphigoid spectrum, the mean age was 72 years. Comorbidities were reported with increasing frequency, as well as treatment options other than systemic corticosteroids, such as adjuvant immunosuppressive agents, which were used to achieve complete remission. This is a report from a tertiary AIBD Referral Center in northern Greece. Our data from a 4-year period contribute to the completion of the global geographic incidence map of AIBD.

[1]  C. Sitaru,et al.  Role of physical factors in the pathogenesis of bullous pemphigoid: Case report series and a comprehensive review of the published work , 2016, The Journal of dermatology.

[2]  D. Zillikens,et al.  Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology , 2015, The British journal of dermatology.

[3]  D. Zillikens,et al.  Pemphigus. S2 Guideline for diagnosis and treatment – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV) , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  A. España,et al.  Epidermolysis bullosa acquisita: a retrospective analysis of 12 patients evaluated in four tertiary hospitals in Spain , 2014, The British journal of dermatology.

[5]  A. Serwin,et al.  Incidence and mortality of bullous pemphigoid in north‐east Poland (Podlaskie Province), 1999–2012: a retrospective bicentric cohort study , 2014, International journal of dermatology.

[6]  D. Sotiriadis,et al.  Clinical significance of anti-desmoglein-1 and -3 circulating autoantibodies in Pemphigus Patients Measured by Area Index and Intensity Score. , 2014, Acta dermato-venereologica.

[7]  M. Brites,et al.  Bullous pemphigoid and comorbidities: a case-control study in Portuguese patients* , 2014, Anais brasileiros de dermatologia.

[8]  D. Sotiriadis,et al.  Association of Autoantibodies to BP180 with Disease Activity in Greek Patients with Bullous Pemphigoid , 2012, Clinical & developmental immunology.

[9]  P. Courville,et al.  Incidence and mortality of bullous pemphigoid in France. , 2012, The Journal of investigative dermatology.

[10]  H. Shimizu,et al.  Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. , 2012, Journal of the American Academy of Dermatology.

[11]  C. Chams‐Davatchi,et al.  Spectrum of autoimmune bullous diseases in Iran: a 10‐year review , 2012, International journal of dermatology.

[12]  M. Hertl,et al.  Autoimmune bullous skin diseases. Part 2: diagnosis and therapy , 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[13]  M. Mokni,et al.  Spectrum of autoimmune blistering dermatoses in Tunisia: an 11‐year study and a review of the literature , 2011, International journal of dermatology.

[14]  M. Jonkman,et al.  The many faces of epidermolysis bullosa acquisita after serration pattern analysis by direct immunofluorescence microscopy , 2011, The British journal of dermatology.

[15]  P. Tuchinda,et al.  Prevalence and clinical features of Thai patients with bullous pemphigoid. , 2011, Asian Pacific journal of allergy and immunology.

[16]  Enno Schmidt,et al.  Modern diagnosis of autoimmune blistering skin diseases. , 2010, Autoimmunity reviews.

[17]  E. Bröcker,et al.  Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany , 2009, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[18]  J. Fairley,et al.  Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. , 2009, The Journal of allergy and clinical immunology.

[19]  R. Hubbard,et al.  Bullous pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population based cohort study , 2008, BMJ : British Medical Journal.

[20]  B. Thiers Rituximab in autoimmune bullous diseases: mixed responses and adverse effects , 2008 .

[21]  C. Sitaru,et al.  Immunopathology and molecular diagnosis of autoimmune bullous diseases , 2007, Journal of cellular and molecular medicine.

[22]  A. Markopoulos,et al.  Epidemiologic survey of pemphigus vulgaris with oral manifestations in northern Greece: Retrospective study of 129 patients , 2007, International journal of dermatology.

[23]  E. Alpsoy,et al.  Pemphigus in the Mediterranean region of Turkey: A study of 148 cases , 2006, International journal of dermatology.

[24]  Z. Naraghi,et al.  Pemphigus: Analysis of 1209 cases , 2005, International journal of dermatology.

[25]  A. Nanda,et al.  Spectrum of autoimmune bullous diseases in Kuwait , 2004, International journal of dermatology.

[26]  C. Scully,et al.  Pemphigus vulgaris: update on etiopathogenesis, oral manifestations, and management. , 2002, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[27]  L. Vaillant,et al.  A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. , 2002, The New England journal of medicine.

[28]  N. Tsankov,et al.  Epidemiology of pemphigus in Sofia, Bulgaria. A 16‐year retrospective study (1980–1995) , 2000, International journal of dermatology.

[29]  B. Rye,et al.  Autoimmune bullous diseases. , 1997, American family physician.